Tam S W
Proc Natl Acad Sci U S A. 1983 Nov;80(21):6703-7. doi: 10.1073/pnas.80.21.6703.
It has been postulated that the psychotomimetic effects of opiates of the benzomorphan series are due to their activity at the sigma receptor. Therefore, the binding of (+/-)-[3H]ethylketocyclazocine ( [3H]EKC), a benzomorphan, to synaptosomal membranes of rat central nervous tissue was studied. Surprisingly, high concentrations of naloxone, a mu, delta, and kappa receptor antagonist, only inhibited about 80% of the specifically bound [3H]EKC in the spinal cord. This suggested that the remaining 20% of the binding sites were not mu, delta, or kappa. The Scatchard plot of the binding of [3H]EKC was nonlinear but became linear in the presence of naloxone (1 microM), suggesting a single class of naloxone-inaccessible receptor sites. This biochemically readily distinguishable receptor type bound the dextrorotatory isomer of EKC stereoselectively. The sigma agonist N-allylnormetazocine [(+)-SKF 10,047] stereoselectively competed with the binding of [3H]EKC to this naloxone-inaccessible binding site. A number of opiates that have psychotomimetic activity also competed for binding to this binding site. This binding site is designated as sigma binding site according to the nomenclature originally suggested by Martin et al. [Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E. & Gilbert, P. E. (1976) J. Pharmacol. Exp. Ther. 197, 517-532]. The drug selectivity and regional distribution of this sigma binding site in the rat central nervous system are different from that of the mu and delta opioid receptors and phencyclidine receptors. The concentration of the sigma binding site is highest in the spinal cord, pons and medulla, and cerebellum.
据推测,苯吗喃类阿片药物的拟精神病效应是由于其对σ受体的活性作用。因此,研究了苯吗喃类药物(±)-[³H]乙基酮环佐辛([³H]EKC)与大鼠中枢神经组织突触体膜的结合情况。令人惊讶的是,高浓度的纳洛酮(一种μ、δ和κ受体拮抗剂)仅抑制了脊髓中约80%的特异性结合[³H]EKC。这表明其余20%的结合位点不是μ、δ或κ受体。[³H]EKC结合的Scatchard图是非线性的,但在纳洛酮(1μM)存在下变为线性,表明存在一类纳洛酮无法作用的单一受体位点。这种在生化上易于区分的受体类型对EKC的右旋异构体具有立体选择性结合。σ激动剂N-烯丙基去甲左啡诺[(+)-SKF 10,047]与[³H]EKC与该纳洛酮无法作用的结合位点的结合具有立体选择性竞争。许多具有拟精神病活性的阿片药物也竞争与该结合位点的结合。根据Martin等人最初提出的命名法[Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E. & Gilbert, P. E. (1976) J. Pharmacol. Exp. Ther. 197, 517 - 532],该结合位点被指定为σ结合位点。大鼠中枢神经系统中该σ结合位点的药物选择性和区域分布与μ和δ阿片受体以及苯环己哌啶受体不同。σ结合位点的浓度在脊髓、脑桥、延髓和小脑中最高。